Atossa Therapeutics Inc ATOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
-
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
-
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
-
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
-
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
-
Stocks to Watch: Atossa Therapeutics, Union Pacific
Trading Information
- Previous Close Price
- $1.95
- Day Range
- $1.96–2.30
- 52-Week Range
- $1.70–19.35
- Bid/Ask
- $2.18 / $2.18
- Shares Outstanding
- 9.98M
- Market Cap
- $22.65M
- Volume/Avg
- 1,078 / 76,235
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
Valuation
|
Metric
|
ATOS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.84 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATOS
|
|---|---|
Quick Ratio | 4.79 |
Current Ratio | 5.69 |
Interest Coverage | — |
Quick Ratio
ATOS
Profitability
|
Metric
|
ATOS
|
|---|---|
Return on Assets (Normalized) | −72.57% |
Return on Equity (Normalized) | −85.44% |
Return on Invested Capital (Normalized) | −89.23% |
Return on Assets
ATOS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?ZFJM^M | LOCK|$CT$ | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>VY^hF^ | LOCK|H?^B< | $76B | |||
| Moderna Inc
MRNA
| LOCK|v?VFrz | LOCK|B#N | $75B | |||
| argenx SE ADR
ARGX
| LOCK|j$kW>& | LOCK|<@ | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@P&>!P$ | LOCK|Xm | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gL$k^K> | LOCK|gCjT | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?!rgb>tm | LOCK|HDm$# | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|r&!>Q>n | LOCK|qVT | $24B | |||
| Incyte Corp
INCY
| LOCK|F?sGn> | LOCK|yJK | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^^Hf!<w | LOCK|PQ | $15B |
United States